Unknown

Dataset Information

0

A Novel RFXANK Mutation in a Chinese Child With MHC II Deficiency: Case Report and Literature Review.


ABSTRACT: Major histocompatibility complex (MHC) II deficiency is a rare primary immunodeficiency disorder that is characterized by the deficiency of MHC class II molecules. The disease is caused by transcription factor mutations including class II transactivator (CIITA), regulatory factor X-5 (RFX5), RFX-associated protein (RFXAP), and RFXAP-containing ankyrin repeat (RFXANK), respectively. Mutations in the RFXANK gene account for >70% of all known patients worldwide. Herein, we reported a 10-month-old boy with MHC II deficiency caused by a novel mutation in the RFXANK gene (c.337 + 1G>C). The boy was admitted to the hospital due to pneumonia and diarrhea at 4 months of age. Genetic analysis revealed a novel homozygous mutation in the RFXANK gene, which derived from the c.337 + 1G>C heterozygous mutations in the RFXANK gene of his parents. The boy died 3 months after diagnosis. More than 200 cases have been reported, and a review of the literature revealed different mutation rates of 4 transcription factors in different countries or regions. This is the first case report of MHC II deficiency from East Asia. We also describe all gene mutations that cause MHC II deficiency and the epidemiology of MHC II deficiency with gene mutations in this paper.

SUBMITTER: Cai YQ 

PROVIDER: S-EPMC7452370 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Novel RFXANK Mutation in a Chinese Child With MHC II Deficiency: Case Report and Literature Review.

Cai Yu Qing YQ   Zhang HangHu H   Wang Xiang Zhi XZ   Xu ChengYun C   Chao Yun Qi YQ   Shu YingYing Y   Tang Lan Fang LF  

Open forum infectious diseases 20200724 8


Major histocompatibility complex (MHC) II deficiency is a rare primary immunodeficiency disorder that is characterized by the deficiency of MHC class II molecules. The disease is caused by transcription factor mutations including class II transactivator (<i>CIITA</i>), regulatory factor X-5 (<i>RFX5</i>), RFX-associated protein (<i>RFXAP</i>), and RFXAP-containing ankyrin repeat (<i>RFXANK</i>), respectively. Mutations in the <i>RFXANK</i> gene account for >70% of all known patients worldwide. H  ...[more]

Similar Datasets

| S-EPMC5348910 | biostudies-literature
| S-EPMC3307667 | biostudies-other
| S-EPMC6441210 | biostudies-literature
| S-EPMC6499615 | biostudies-literature
| S-EPMC4412451 | biostudies-literature
| S-EPMC5833739 | biostudies-literature
| S-EPMC9309486 | biostudies-literature
| S-EPMC10413980 | biostudies-literature
| S-EPMC4502623 | biostudies-literature